Palatin Technologies (PTN) said it started enrollment in a phase 2b trial of bremelanotide to treat diabetic kidney disease.The company added that patient screening/enrollment had begun.
Galecto (GLTO) said its medicine GB1211 helped reduce certain liver enzymes in patients with decompensated cirrhosis in a phase 1b/2a trial.The study, dubbed GULLIVER-2, evaluated.
Germany's Affimed (AFMD) and San Diego-based Artiva Biotherapeutics signed an agreement to jointly develop and commercialize a combination therapy to treat cancer.The combo.
Last month, we asked local college leaders about why 2022 is such an important year for higher ed, how the pandemic changed local ed, and what new options are available this year.